---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034688"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:54:46.388132+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025

## Summary
- Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.
- Collaboration revenue $2.1M in Q4 and $7.9M for FY2023, up from $1.4M and $5.7M prior year.
- Loss from operations improved to $19.8M (Q4) and $76.2M (FY2023) vs $21.0M and $90.3M.
- BDC-1001 Phase 2 advancing in five HER2-positive tumor cohorts; 29% ORR at RP2D reported at ESMO 2023.
- BDC-3042 Phase 1 cleared three dose levels without DLT; now enrolling fourth cohort.

## SEC filing metadata
- accession: 0000950170-24-034688
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/0000950170-24-034688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/bolt-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034688
- JSON: https://secwatch.observer/filing/0000950170-24-034688.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034688.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/0000950170-24-034688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.